Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
56
SUPN Quote, Financials, Valuation and Earnings
Last price:
$51.14
Seasonality move
:
6.72%
Day range:
$50.45 - $52.39
52-week range:
$29.16 - $57.65
Dividend yield:
0%
P/E ratio:
41.17x
P/S ratio:
4.23x
P/B ratio:
2.79x
Volume:
1.2M
Avg. volume:
619.6K
1-year change:
34.29%
Market cap:
$2.9B
Revenue:
$661.8M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$194M | $0.45 | 29.51% | 60.84% | $61.33 |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$169M | $0.79 | 2.12% | 24.53% | $31.71 |
|
ASMB
Assembly Biosciences, Inc.
|
$9.3M | -$0.50 | 0.89% | -46.09% | $47.75 |
|
BBIO
BridgeBio Pharma, Inc.
|
$167.6M | -$0.64 | 43.65% | -27.31% | $88.95 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142.7M | $0.59 | 0.87% | 32.59% | $34.86 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.94 | -- | -131.2% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$51.11 | $61.33 | $2.9B | 41.17x | $0.00 | 0% | 4.23x |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$27.74 | $31.71 | $1.3B | 12.30x | $0.00 | 0% | 1.89x |
|
ASMB
Assembly Biosciences, Inc.
|
$31.74 | $47.75 | $502M | -- | $0.00 | 0% | 7.35x |
|
BBIO
BridgeBio Pharma, Inc.
|
$77.25 | $88.95 | $14.9B | -- | $0.00 | 0% | 41.59x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$22.72 | $34.86 | $2.8B | 13.26x | $0.00 | 0% | 4.99x |
|
VKTX
Viking Therapeutics, Inc.
|
$31.99 | $93.39 | $3.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.793 | 1.55% | 1.37x |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
45.82% | 0.275 | 53.17% | 2.07x |
|
ASMB
Assembly Biosciences, Inc.
|
1.49% | 3.671 | 0.68% | 4.37x |
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.558 | 27% | 3.52x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 0.864 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$95M | $25.3M | 7.98% | 14.9% | 13.2% | $47.2M |
|
ASMB
Assembly Biosciences, Inc.
|
$10.8M | -$10.9M | -64.14% | -67.09% | -100.87% | -$15.2M |
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Supernus Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SUPN or AMPH?
Amphastar Pharmaceuticals, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 9.04%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B -
What do Analysts Say About SUPN or AMPH?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 20%. On the other hand Amphastar Pharmaceuticals, Inc. has an analysts' consensus of $31.71 which suggests that it could grow by 14.33%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 AMPHAmphastar Pharmaceuticals, Inc.2 4 0 -
Is SUPN or AMPH More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.673, which suggesting that the stock is 32.701% less volatile than S&P 500. In comparison Amphastar Pharmaceuticals, Inc. has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.551%.
-
Which is a Better Dividend Stock SUPN or AMPH?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amphastar Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amphastar Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or AMPH?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Amphastar Pharmaceuticals, Inc. quarterly revenues of $191.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Amphastar Pharmaceuticals, Inc.'s net income of $17.4M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Amphastar Pharmaceuticals, Inc.'s PE ratio is 12.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.23x versus 1.89x for Amphastar Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.23x 41.17x $192.1M -$45.1M AMPHAmphastar Pharmaceuticals, Inc.1.89x 12.30x $191.8M $17.4M
-
Which has Higher Returns SUPN or ASMB?
Assembly Biosciences, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -85.24%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Assembly Biosciences, Inc.'s return on equity of -67.09%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M -
What do Analysts Say About SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 20%. On the other hand Assembly Biosciences, Inc. has an analysts' consensus of $47.75 which suggests that it could grow by 50.44%. Given that Assembly Biosciences, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 ASMBAssembly Biosciences, Inc.4 0 0 -
Is SUPN or ASMB More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.673, which suggesting that the stock is 32.701% less volatile than S&P 500. In comparison Assembly Biosciences, Inc. has a beta of 1.143, suggesting its more volatile than the S&P 500 by 14.321%.
-
Which is a Better Dividend Stock SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assembly Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Assembly Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or ASMB?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Assembly Biosciences, Inc. quarterly revenues of $10.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Assembly Biosciences, Inc.'s net income of -$9.2M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Assembly Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.23x versus 7.35x for Assembly Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.23x 41.17x $192.1M -$45.1M ASMBAssembly Biosciences, Inc.7.35x -- $10.8M -$9.2M
-
Which has Higher Returns SUPN or BBIO?
BridgeBio Pharma, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -153.22%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M -
What do Analysts Say About SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 20%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $88.95 which suggests that it could grow by 15.14%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 BBIOBridgeBio Pharma, Inc.15 1 0 -
Is SUPN or BBIO More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.673, which suggesting that the stock is 32.701% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.877%.
-
Which is a Better Dividend Stock SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or BBIO?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.23x versus 41.59x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.23x 41.17x $192.1M -$45.1M BBIOBridgeBio Pharma, Inc.41.59x -- $120.7M -$184.9M
-
Which has Higher Returns SUPN or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 35.57%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About SUPN or CPRX?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 20%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 53.42%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is SUPN or CPRX More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.673, which suggesting that the stock is 32.701% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock SUPN or CPRX?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or CPRX?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.23x versus 4.99x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.23x 41.17x $192.1M -$45.1M CPRXCatalyst Pharmaceuticals, Inc.4.99x 13.26x $148.4M $52.8M
-
Which has Higher Returns SUPN or VKTX?
Viking Therapeutics, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of --. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 20%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 191.93%. Given that Viking Therapeutics, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is SUPN or VKTX More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.673, which suggesting that the stock is 32.701% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.
-
Which is a Better Dividend Stock SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or VKTX?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.23x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.4.23x 41.17x $192.1M -$45.1M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
